Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05172726 · ClinicalTrials.gov registry record · Phase 3
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
A Phase 3 study of Plaque Psoriasis, sponsored by Organon and.
- Active
- Registry status
- Phase 3
- Development phase
- 58
- Enrollment target
- 19
- Study locations
NCT05172726: Active Phase 3 study of Plaque Psoriasis, sponsored by Organon and.
NCT05172726 is a Phase 3 study of Plaque Psoriasis that is active but no longer recruiting, run by Organon and. The registered enrollment target is 58 participants, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (86% lower). The trial reports 19 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05172726, a Phase 3 study of Plaque Psoriasis, is active but no longer recruiting, sponsored by Organon and.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 58 participants
- Enrollment target
- 19
- Study locations
Study Summary
This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis.
Primary Outcome
Incidence, frequency, and duration of treatment emergent AEs and SAEs
Conditions Studied
Interventions
- DRUG tapinarof cream, 1%
Study Locations (19)
Florida
- RM Medical Research - Miami Lakes
- San Marcus Research Clinic, Inc. - Miami Lakes
- Olympian Clinical Research - Tampa
Ontario
- Lynderm Research Inc. - Markham
- Alliance Clinical Trials - Waterloo
- Whitby Health Centre Dermatology Trials - Whitby
California
- First OC Dermatology - Fountain Valley
- Mission Dermatology Center - Rancho Santa Margarita
Indiana
- Dawes Fretzin Clinical Research Group - Indianapolis
- Options Research Group - West Lafayette
Alberta
- Dermatology Research Institute Inc. - Calgary
- Rejuvenation Laser Dermatology Clinics - Edmonton
Arkansas
- Northwest Arkansas Clinical Trials Center, PLLC - Rogers
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
Ohio
- Wright State Physicians Pharmacology Translational Unit - Fairborn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2021-12-02 |
| Est. Completion | 2026-10 |
| Phase | Phase 3 |
What the registry record for NCT05172726 still lists
NCT05172726 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which tapinarof cream, 1% is the first listed.
NCT05172726 lists 19 locations in 12 states (Florida, Ontario, California).
Frequently Asked Questions
What is clinical trial NCT05172726 about?
NCT05172726 is a clinical study titled "Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects". This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis.
What is the current status of trial NCT05172726?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 58 participants. The study started on 2021-12-02. Estimated completion is 2026-10.
What conditions does trial NCT05172726 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT05172726?
The interventions under investigation include: tapinarof cream, 1% (DRUG).
Who is sponsoring clinical trial NCT05172726?
This trial is sponsored by Organon and, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05172726 being conducted?
This trial has 19 study locations across Arkansas, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05172726's enrollment target sits among peer trials
58 36th of 45 higher than 10 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI